Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

LYB004 25µg

Phase 1Biologic

GGuangzhou Patronus Biotech Co., Ltd.

LYB004 25µg is one of 2 biologic programs targeting Recombinant Zoster Vaccine. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Recombinant Zoster VaccineActive, not recruiting

Recombinant Zoster VaccinePhase 1

Active, not recruiting

Competition

Competitive Landscape

1 competitor in Recombinant Zoster Vaccine

#DrugCompanyPhaseTrials

Recombinant Zoster Vaccine

MMAXVAX Biotechnology Limited Liability Company

LYB004 25µg

GGuangzhou Patronus Biotech Co., Ltd.

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Recombinant Zoster Vaccine1 trial

A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years

Active, not recruiting·GGuangzhou Patronus Biotech Co., Ltd.·Phase 1·NCT06335849·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for LYB004 25µg. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — LYB004 25µg compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for LYB004 25µg. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangzhou Patronus Biotech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: GGuangzhou Patronus Biotech Co., Ltd.

Related News